Keywords: Breast, Breast, DCE-MRI
Motivation: Gadopiclenol is a recently-approved MR contrast agent that has a significantly higher relaxivity than other contrast agents on the market. Higher background parenchymal enhancement (BPE) in breast MRI could potentially lead to a higher false positive rate in screening studies.
Goal(s): To compare enhancement characteristics of background parenchyma in abbreviated breast MRI (AbMR) screening studies acquired with two different contrast agents.
Approach: We retrospectively reviewed sequential screening AbMR scans of 264 patients who were imaged with both gadopiclenol and gadoteridol and quantitatively measured BPE.
Results: BPE was slightly higher in images acquired with gadopiclenol despite its dose being lower: 23%±12% vs 21%±9% (p<0.01).
Impact: Abbreviated breast MRIs acquired with 0.05mmol/kg gadopiclenol showed slightly higher levels of signal enhancement in background parenchyma than those acquired with 0.1mmol/kg gadoteridol. Further investigation is underway to determine whether these differences lead to a higher false positive rate.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords